a Phase 2 study with NBI-'568 in bipolar mania,.
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs HTL-0016878 (Primary)
- Indications Bipolar depression
- Focus Adverse reactions
- 20 Jan 2025 New trial record
- 14 Jan 2025 company expected to initiate a Phase 2 study with NBI-568 in bipolar mania, a mental health condition that causes extreme mood swings, in 2H 2025.